DPYD, TYMS, TYMP, TK1, and TK2 Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy
Table 4
Univariate and multivariate regression analysis of prognostic indicators and nonresponse status for 60 locally advanced rectal cancer patients.
Parameters
Number
Univariate analysis
value
Multivariate analysis
value
Hazard ratio (95% CI)
Hazard ratio (95% CI)
Sex (female/male)
26/34
0.654 (0.309–1.384)
0.251
0.088 (0.005–1.613)
0.102
Age (≥60/<60)
38/22
0.941 (0.464–1.908)
1.000
0.093 (0.003–2.979)
0.179
Tumor size (≥5 cm/<5 cm)
14/46
1.643 (0.831–3.250)
0.179
4.658 (0.145–50.100)
0.385
Stage (UICC)a (II/III)
12/48
1.250 (0.573–2.727)
0.737
7.244 (0.114–458.695)
0.349
Clinical T-stage (T4/T3)
6/54
0.947 (0.289–3.108)
1.000
0.752 (0.023–24.539)
0.873
Clinical N-stage (N2/N1 + N0)
25/35
0.862 (0.421–1.762)
0.681
0.396 (0.011–14.706)
0.616
Chemotherapy (capecitabine/5-FU)
36/24
0.606 (0.306–1.200)
0.151
0.061 (0.002–1.745)
0.102
Differentiationb (PD + MD/WD)
51/2
0.627 (0.508–0.775)
0.531
0.000 (0.000–0.000)
0.999
Distance to anus (<5 cm/≥5 cm)
38/22
0.637 (0.324–1.253)
0.196
0.107 (0.002–5.908)
0.275
Vascular invasion (Yes/No)
52/8
0.923 (0.350–2.434)
1.000
2.022 (0.084–48.564)
0.664
Perineural invasion (Yes/No)
40/20
0.455 (0.233–0.886)
0.022
0.043 (0.002–1.0780)
0.056
Pre-CCRT CEAc (ng/mL) (>2.5/≤2.5)
44/16
0.909 (0.428–1.933)
0.807
0.314 (0.004–23.578)
0.599
Pre-CCRT CEAc (ng/mL) (>5/≤5)
27/33
1.111 (0.558–2.213)
0.765
0.407 (0.018–8.967)
0.569
Chipd result (negative/positive)
21/39
7.893 (3.049–20.434)
<0.001
22.704 (3.055–235.448)
0.014
UICC: The American Joint Commission on Cancer/International Union Against Cancer (AJCC/UICC, 2002).
bWD: well differentiated, MD: moderately differentiated, PD: poorly differentiated.
cCEA: carcinoembryonic antigen.
dChip: panel of multiple genetic biomarkers.
